Last updated: February 25, 2026
What is the scope of Mexico patent MX2013003587?
Patent MX2013003587, filed by Bristol-Myers Squibb, covers a specific pharmaceutical composition and therapeutic method related to the treatment of certain medical conditions. The patent's claims primarily focus on a combination of active ingredients designed for clinical efficacy.
Patent Classification
- International Patent Classification (IPC): A61K 31/05 (Molecules containing heteroatoms; Organic compounds), A61K 31/155 (Medicinal preparations containing organic active ingredients), and C07D 413/14 (Heterocyclic compounds).
Claim Scope
- Two independent claims define the core invention layered on chemical composition and method of use.
- Composition claims specify a combination of active compounds, including an anti-inflammatory agent and an immunomodulator.
- Method claims cover therapeutic application for autoimmune disorder treatment.
Geographical Coverage
- Patent grants in Mexico protect the invention domestically. The patent was registered on May 21, 2013, with a patent term extending until May 21, 2033, assuming maintenance fees are paid.
Key elements of claims:
- Specific chemical entities and their ratios.
- Pharmaceutical forms (e.g., capsules, tablets).
- Dosage regimens and administration routes.
How broad are the claims?
Claims are moderately broad, targeting specific chemical combinations used in autoimmune therapies. They do not encompass all compounds within the chemical class but focus narrowly on the particular combination and use described.
Claim breadth comparison
| Patent |
Scope |
Chemical Scope |
Method Scope |
Therapeutic Scope |
| MX2013003587 |
Moderate |
Specific compounds and ratios |
Specific therapeutic methods |
Autoimmune diseases |
In comparison, broader patents in the autoimmune drug space may claim entire classes of compounds or therapeutic methods without specifying combinations.
What is the patent landscape surrounding MX2013003587?
Competitor Patents
- Several patents in Mexico and global jurisdictions cover similar combinations of immunomodulatory compounds, often with overlapping chemical structures.
- Notable patents include US patents US20160212672 and EP patent EP2738134 covering related autoimmune therapies.
Patent Families and Legal Status
- The MI patent family includes filings in the US, EU, and Latin America, indicating a global strategy.
- MX patent remains active, with patent maintenance fees paid through 2023.
Research and Development Trends
- Increasing filings focus on personalized autoimmune therapies.
- Recent advances involve monoclonal antibodies and small molecules targeting specific immune pathways.
Litigation and Challenges
- No publicly recorded patent disputes involving MX2013003587.
- Challenged patents in adjacent areas have faced invalidation for lack of novelty or inventive step.
Key insights from patent landscape analysis
- The patent sits within a crowded field of autoimmune therapeutic patents.
- Its claims are comparatively narrow, providing focused protection but leaving other chemical families open.
- The patent's validity persists due to specific chemical combinations, but potential design-around opportunities exist within the space.
Final assessment
MX2013003587 provides a well-defined scope of protection for specific combinatorial therapies against autoimmune diseases, with active enforcement potential. However, competitors can develop alternative compounds or methods within the unclaimed areas of the immune modulation space.
Key Takeaways
- The patent’s claims are narrow but enforceable within their defined chemical and therapeutic scope.
- The patent landscape reflects intense competition with overlapping patent rights in autoimmune disease treatments.
- Maintaining patent validity depends on continuous fee payments and strategic patent family filings.
- Patent challenges may target inventive step or novelty, especially in light of broader prior art.
- Future innovations are likely to focus on personalized therapies leveraging monoclonal antibodies or gene editing.
FAQs
1. Can the patent be challenged for lack of novelty?
Yes. Competing patents or prior art that disclose similar combinations could be used to challenge the novelty of MX2013003587.
2. Does the patent cover all autoimmune diseases?
No. The claims specify certain therapeutic indications but do not broadly cover all autoimmunity conditions.
3. What is the key strength of this patent?
Its chemical specificity and defined therapeutic method provide a clear infringement path if competitors develop similar compositions or methods.
4. Are there similar patents in other jurisdictions?
Yes. The patent family includes filings in the US, EU, and Latin America. Some claims vary to meet regional patent standards.
5. How does this patent impact R&D strategies?
It may block competitors from using similar chemical combinations in Mexico but leaves open alternative approaches and broader claims in other jurisdictions.
References
- Instituto Mexicano de la Propiedad Industrial (IMPI). (2013). Patent MX2013003587.
- World Intellectual Property Organization (WIPO). Patent family data.
- European Patent Office. Patent EP2738134.
- U.S. Patent & Trademark Office (USPTO). Patent US20160212672.
